ArticleBMC infectious diseases2008
An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models.
Article in BMC infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Dipyridamole augments the antiinflammatory response during human endotoxemia.Critical care (London, England) · 2011Trial
- An NT5E loss-of-function variant permits tissue inflammation and hypertension in systemic lupus erythematosus.iScience · 2026Article
- The Cholinergic Amelioration of Sepsis-Induced Baroreflex Dysfunction and Brainstem Inflammation Is Negated by Central Adenosine A3 Receptors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- [Advances in the study of the role of adenosine 2A receptor in liver injury].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Review
- Synapomorphic features of hepatic and pulmonary vasculatures include comparable purinergic signaling responses in host defense and modulation of inflammation.American journal of physiology. Gastrointestinal and liver physiology · 2021Review
- Deletion of the adenosine APurinergic signalling · 2020Article
- Targeting Purinergic Signaling in the Dynamics of Disease Progression in Sepsis.Frontiers in pharmacology · 2020Article
- Anti-inflammatory effect of a novel locally acting APurinergic signalling · 2018Article
- CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.Journal of hepatology · 2017Article
- A2A adenosine receptor upregulation correlates with disease activity in patients with systemic lupus erythematosus.Arthritis research & therapy · 2016Article
- Purinergic regulation of the immune system.Nature reviews. Immunology · 2016Review
- Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats.Brain, behavior, and immunity · 2015Article
- The A2A adenosine receptor is a dual coding gene: a novel mechanism of gene usage and signal transduction.The Journal of biological chemistry · 2014Article
- Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation.Journal of inflammation (London, England) · 2014Article
- The adenosine A₂A receptor - myocardial protectant and coronary target in endotoxemia.International journal of cardiology · 2013Article
- Article
- Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.BMC infectious diseases · 2012Article
- Regulation of lymphocyte function by adenosine.Arteriosclerosis, thrombosis, and vascular biology · 2012Review
- Effects of adenosine A₂A receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice.BMC infectious diseases · 2012Article
- Immunological alterations mediated by adenosine during host-microbial interactions.Immunologic research · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe pathophysiology of sepsis is due in part to early systemic inflammation. Here we describe molecular and cellular responses, as well as survival, in A 2A adenosine receptor (AR) agonist treated and untreated animals during experimental sepsis.
methodsSepsis was induced in mice by intraperitoneal inoculation of live bacteria (Escherichia coli or Staphylococcus aureus) or lipopolysaccharide (LPS). Mice inoculated with live bacteria were treated with an A 2A AR agonist (ATL313) or phosphate buffered saline (PBS), with or without the addition of a dose of ceftriaxone. LPS inoculated mice were treated with ATL313 or PBS. Serum cytokines and chemokines were measured sequentially at 1, 2, 4, 8, and 24 hours after LPS was administered. In survival studies, mice were followed until death or for 7 days.
resultsThere was a significant survival benefit in mice infected with live E. coli (100% vs. 20%, p = 0.013) or S. aureus (60% vs. 20%, p = 0.02) when treated with ATL313 in conjunction with an antibiotic versus antibiotic alone. ATL313 also improved survival from endotoxic shock when compared to PBS treatment (90% vs. 40%, p = 0.005). The serum concentrations of TNF-alpha, MIP-1 alpha, MCP-1, IFN-gamma, and IL-17 were decreased by ATL313 after LPS injection (p < 0.05). Additionally, ATL313 increased the concentration of IL-10 under the same conditions (p < 0.05). Circulating white blood cell concentrations were higher in ATL313 treated animals (p < 0.01).
conclusionFurther studies are warranted to determine the clinical utility of ATL313 as a novel treatment for sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.